📊 VNDA Key Takeaways
Is Vanda Pharmaceuticals Inc. (VNDA) a Good Investment?
Vanda Pharmaceuticals is in severe financial distress with unsustainable cash burn and structural profitability challenges. The company is losing $110M+ annually in free cash flow on flat $216M revenue, creating a less-than-one-year cash runway at current burn rates. Despite zero debt and strong liquidity ratios, the negative 70% operating margin indicates fundamental cost structure misalignment that cannot support ongoing operations.
Why Buy Vanda Pharmaceuticals Inc. Stock? VNDA Key Strengths
- Zero long-term debt provides financial flexibility
- Strong current and quick ratios (2.39x, 2.38x) indicate short-term liquidity
- Gross margin of 28.2% shows products generate positive margins at the product level
VNDA Stock Risks: Vanda Pharmaceuticals Inc. Investment Risks
- Negative free cash flow of $110.4M with only $84.9M cash balance = sub-one-year runway
- Operating losses of $151.2M exceed revenue of $216.1M, indicating structurally broken economics
- Flat YoY revenue growth with massive operating expenses suggests failed R&D strategy or market challenges
- Cash burn unsustainable without significant operational restructuring or asset sales
- Net loss of $220.5M represents 102% of revenue, indicating severe operating inefficiency
Key Metrics to Watch
- Operating cash flow trajectory and cash runway duration
- Quarterly revenue trends and any pipeline approvals
- R&D spending levels and their relationship to development success
- Any debt financing or dilutive equity raises
- Operating expense reductions or restructuring announcements
Vanda Pharmaceuticals Inc. (VNDA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.39x current ratio provides a solid financial cushion.
VNDA Profit Margin, ROE & Profitability Analysis
VNDA vs Healthcare Sector: How Vanda Pharmaceuticals Inc. Compares
How Vanda Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vanda Pharmaceuticals Inc. Stock Overvalued? VNDA Valuation Analysis 2026
Based on fundamental analysis, Vanda Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vanda Pharmaceuticals Inc. Balance Sheet: VNDA Debt, Cash & Liquidity
VNDA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vanda Pharmaceuticals Inc.'s revenue has declined by 20% over the 5-year period, indicating business contraction. The most recent EPS of $0.04 reflects profitable operations.
VNDA Revenue Growth, EPS Growth & YoY Performance
VNDA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $47.7M | -$4.1M | $-0.09 |
| Q2 2025 | $50.5M | -$4.1M | $-0.08 |
| Q1 2025 | $47.5M | -$4.1M | $-0.07 |
| Q3 2024 | $38.8M | $137.0K | $0.00 |
| Q2 2024 | $46.1M | $1.5M | $0.03 |
| Q1 2024 | $47.5M | $3.3M | $0.06 |
| Q3 2023 | $38.8M | $137.0K | $0.00 |
| Q2 2023 | $46.1M | $1.5M | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vanda Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
VNDA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vanda Pharmaceuticals Inc. (CIK: 0001347178)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VNDA
What is the AI rating for VNDA?
Vanda Pharmaceuticals Inc. (VNDA) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VNDA's key strengths?
Claude: Zero long-term debt provides financial flexibility. Strong current and quick ratios (2.39x, 2.38x) indicate short-term liquidity.
What are the risks of investing in VNDA?
Claude: Negative free cash flow of $110.4M with only $84.9M cash balance = sub-one-year runway. Operating losses of $151.2M exceed revenue of $216.1M, indicating structurally broken economics.
What is VNDA's revenue and growth?
Vanda Pharmaceuticals Inc. reported revenue of $216.1M.
Does VNDA pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
Where can I find VNDA SEC filings?
Official SEC filings for Vanda Pharmaceuticals Inc. (CIK: 0001347178) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VNDA's EPS?
Vanda Pharmaceuticals Inc. has a diluted EPS of $-3.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VNDA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vanda Pharmaceuticals Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VNDA stock overvalued or undervalued?
Valuation metrics for VNDA: ROE of -67.4% (sector avg: 15%), net margin of -102.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VNDA stock in 2026?
Our dual AI analysis gives Vanda Pharmaceuticals Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VNDA's free cash flow?
Vanda Pharmaceuticals Inc.'s operating cash flow is $-109.4M, with capital expenditures of $998.0K. FCF margin is -51.1%.
How does VNDA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -102.0% (avg: 12%), ROE -67.4% (avg: 15%), current ratio 2.39 (avg: 2).